FAQ on Nutriband Inc.'s AVERSA(TM) Transdermal Pain Solution and BioMedWire Podcast Feature

What is Nutriband Inc.’s AVERSA(TM) platform?

AVERSA(TM) is Nutriband’s internally developed platform designed to deter abuse of opioid patches by making them difficult to manipulate for non-medical use, aiming to improve safety while maintaining accessibility for patients in need.

Why is the development of AVERSA(TM) significant?

The development is significant due to the opioid crisis, which has led to stigma and liability concerns around opioids, leaving many pain patients without adequate care. AVERSA(TM) seeks to restore prescriber and payer confidence in transdermal opioid therapies.

How does AVERSA(TM) aim to impact the fentanyl patch market?

AVERSA(TM) aims to close the care gap in the fentanyl patch market, which has contracted from $4 billion in 2016 to under $1 billion today, by improving the safety of these therapies for the persistent patient population needing them.

Who is Gareth Sheridan and what is his role in Nutriband Inc.?

Gareth Sheridan is the Co-Founder and CEO of Nutriband Inc., who discussed the company’s focus on transdermal drug delivery systems and the AVERSA(TM) platform on the BioMedWire Podcast.

Where can I listen to the BioMedWire Podcast featuring Nutriband Inc.?

The podcast episode featuring Nutriband Inc. can be accessed through the link provided in the content: BioMedWire Podcast.

What is the main focus of Nutriband Inc.’s development pipeline?

Nutriband Inc.’s development pipeline focuses on transdermal drug delivery systems, particularly in the underserved area of pain management, with AVERSA(TM) being a key innovation aimed at deterring abuse of opioid patches.

How can I view the full press release about Nutriband Inc.’s feature on the BioMedWire Podcast?

The full press release can be viewed at the following link: https://ibn.fm/RKA5p.

What is IBN and its role in the life sciences industry?

IBN is a financial brand network that showcases innovators across the life sciences industry, providing access to wire solutions, article syndication, press release enhancement, and full-scale distribution to a growing audience.